SCHEMBL3769953

SCHEMBL3769953

O=C(CN1CCN(C(=O)c2ccccc2C(F)(F)F)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
HTR2B P41595 1/20 0.52
MAPK14 Q16539 1/20 0.52
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 2/20 0.52
CHRM1 P11229 2/20 0.50
MGLL Q99685 2/20 0.48
TP53BP1 Q12888 1/20 0.47
L3MBTL3 Q96JM7 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD11B1 P28845 1/20 0.46
PARP1 P09874 1/20 0.46
SCD O00767 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CCR5 P51681 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774202 0.85 RBP4 (0.53) KDM4EALDH1A1SMN1; SMN2PARP1MEN1
SCHEMBL3773954 0.85 MEN1 (0.62) CYP2C9CYP2C19MAPK14KDM4EALDH1A1
SCHEMBL3769769 0.85 KDM4E (0.60) KDM4EALDH1A1CYP1A2CYP2D6SMN1; SMN2
SCHEMBL3805269 0.84 ALDH1A1 (0.47) KDM4EALDH1A1CYP1A2CYP2D6SMN1; SMN2
SCHEMBL3767746 0.84 HSD11B1 (0.51) KDM4EALDH1A1MGLLTP53BP1L3MBTL3
SCHEMBL3770797 0.83 L3MBTL3 (0.50) KDM4EALDH1A1TP53BP1L3MBTL3L3MBTL1
SCHEMBL3767212 0.83 HTT (0.56) CYP2C9CYP2C19HTR2BMAPK14KDM4E
SCHEMBL3773907 0.83 KDM2B (0.53) CYP2C9CYP2C19HTR2BMAPK14KDM4E
SCHEMBL3762901 0.81 TSHR (0.55) KDM4EALDH1A1TP53BP1L3MBTL3L3MBTL1
SCHEMBL3780472 0.81 ALDH1A1 (0.59) KDM4EALDH1A1TP53BP1L3MBTL3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 CYP2C9 2811/4885CYP2C19 1971/4885HTR2B 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.